Research ExplorerPublicationsRegional differences in metastatic urothelial carcinoma of t...

Regional differences in metastatic urothelial carcinoma of the urinary bladder patients across the United States SEER registries

Standard

Regional differences in metastatic urothelial carcinoma of the urinary bladder patients across the United States SEER registries. / Garcia, Cristina Cano; Tappero, Stefano; Piccinelli, Mattia Luca; Barletta, Francesco; Incesu, Reha-Baris; Morra, Simone; Scheipner, Lukas; Baudo, Andrea; Tian, Zhe; Saad, Fred; Shariat, Shahrokh F; Carmignani, Luca; Ahyai, Sascha; Longo, Nicola; Tilki, Derya; Briganti, Alberto; De Cobelli, Ottavio; Terrone, Carlo; Banek, Severine; Kluth, Luis; Chun, Felix K H; Karakiewicz, Pierre I.

In: CUAJ-CAN UROL ASSOC, Vol. 17, No. 12, 12.2023, p. E412-419.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Garcia, CC, Tappero, S, Piccinelli, ML, Barletta, F, Incesu, R-B, Morra, S, Scheipner, L, Baudo, A, Tian, Z, Saad, F, Shariat, SF, Carmignani, L, Ahyai, S, Longo, N, Tilki, D, Briganti, A, De Cobelli, O, Terrone, C, Banek, S, Kluth, L, Chun, FKH & Karakiewicz, PI 2023, 'Regional differences in metastatic urothelial carcinoma of the urinary bladder patients across the United States SEER registries', CUAJ-CAN UROL ASSOC, vol. 17, no. 12, pp. E412-419. https://doi.org/10.5489/cuaj.8442

APA

Garcia, C. C., Tappero, S., Piccinelli, M. L., Barletta, F., Incesu, R-B., Morra, S., Scheipner, L., Baudo, A., Tian, Z., Saad, F., Shariat, S. F., Carmignani, L., Ahyai, S., Longo, N., Tilki, D., Briganti, A., De Cobelli, O., Terrone, C., Banek, S., ... Karakiewicz, P. I. (2023). Regional differences in metastatic urothelial carcinoma of the urinary bladder patients across the United States SEER registries. CUAJ-CAN UROL ASSOC, 17(12), E412-419. https://doi.org/10.5489/cuaj.8442

Vancouver

Garcia CC, Tappero S, Piccinelli ML, Barletta F, Incesu R-B, Morra S et al. Regional differences in metastatic urothelial carcinoma of the urinary bladder patients across the United States SEER registries. CUAJ-CAN UROL ASSOC. 2023 Dec;17(12):E412-419. https://doi.org/10.5489/cuaj.8442

Bibtex

@article{0fff5da78e274cffabd085aaababc7e0,
title = "Regional differences in metastatic urothelial carcinoma of the urinary bladder patients across the United States SEER registries",
abstract = "INTRODUCTION: Despite advances in treatment, metastatic urothelial carcinoma of the urinary bladder (mUCUB) is associated with high mortality and treatment risk. We tested for regional differences in mUCUB within a large-scale, population-based database.METHODS: Using the Surveillance, Epidemiology and End Results (SEER) database (2010-2018), patient (age, sex, race/ethnicity), tumor (T-stage, N-stage, number of metastatic sites), and treatment (systemic therapy, radical cystectomy) characteristics were tabulated for mUCUB patients according to 11 SEER registries. Multinomial regression models and multivariable Cox regression models tested overall mortality (OM), adjusting for patient, tumor and treatment characteristics.RESULTS: In 4817 mUCUB patients, registry-specific patient counts ranged from 1855 (38.5%) to 105 (2.2%). Important inter-regional differences existed for race/ethnicity (3-36% for others than non-Hispanic Whites), N-stage (28-39% for N1-3, 44-58% in N0, 8-22% for unknown N-stage), systemic therapy (38-54%) and radical cystectomy (3-11%). In multivariable analyses adjusting for these patient, tumor, and treatment characteristics, one registry exhibited significantly lower OM (SEER registry 10: hazard ratio [HR] 0.83) and two other registries exhibited significantly higher OM (SEER registries 9: HR 1.13; SEER registry 8: HR 1.24) relative to the largest reference registry (n=1855).CONCLUSIONS: We identified important regional differences that included patient, tumor, and treatment characteristics. Even after adjustment for these characteristics, important OM differences persisted, which may warrant more detailed investigation.",
author = "Garcia, {Cristina Cano} and Stefano Tappero and Piccinelli, {Mattia Luca} and Francesco Barletta and Reha-Baris Incesu and Simone Morra and Lukas Scheipner and Andrea Baudo and Zhe Tian and Fred Saad and Shariat, {Shahrokh F} and Luca Carmignani and Sascha Ahyai and Nicola Longo and Derya Tilki and Alberto Briganti and {De Cobelli}, Ottavio and Carlo Terrone and Severine Banek and Luis Kluth and Chun, {Felix K H} and Karakiewicz, {Pierre I}",
year = "2023",
month = dec,
doi = "10.5489/cuaj.8442",
language = "English",
volume = "17",
pages = "E412--419",
journal = "CUAJ-CAN UROL ASSOC",
issn = "1911-6470",
publisher = "Canadian Medical Association",
number = "12",

}

RIS

TY - JOUR

T1 - Regional differences in metastatic urothelial carcinoma of the urinary bladder patients across the United States SEER registries

AU - Garcia, Cristina Cano

AU - Tappero, Stefano

AU - Piccinelli, Mattia Luca

AU - Barletta, Francesco

AU - Incesu, Reha-Baris

AU - Morra, Simone

AU - Scheipner, Lukas

AU - Baudo, Andrea

AU - Tian, Zhe

AU - Saad, Fred

AU - Shariat, Shahrokh F

AU - Carmignani, Luca

AU - Ahyai, Sascha

AU - Longo, Nicola

AU - Tilki, Derya

AU - Briganti, Alberto

AU - De Cobelli, Ottavio

AU - Terrone, Carlo

AU - Banek, Severine

AU - Kluth, Luis

AU - Chun, Felix K H

AU - Karakiewicz, Pierre I

PY - 2023/12

Y1 - 2023/12

N2 - INTRODUCTION: Despite advances in treatment, metastatic urothelial carcinoma of the urinary bladder (mUCUB) is associated with high mortality and treatment risk. We tested for regional differences in mUCUB within a large-scale, population-based database.METHODS: Using the Surveillance, Epidemiology and End Results (SEER) database (2010-2018), patient (age, sex, race/ethnicity), tumor (T-stage, N-stage, number of metastatic sites), and treatment (systemic therapy, radical cystectomy) characteristics were tabulated for mUCUB patients according to 11 SEER registries. Multinomial regression models and multivariable Cox regression models tested overall mortality (OM), adjusting for patient, tumor and treatment characteristics.RESULTS: In 4817 mUCUB patients, registry-specific patient counts ranged from 1855 (38.5%) to 105 (2.2%). Important inter-regional differences existed for race/ethnicity (3-36% for others than non-Hispanic Whites), N-stage (28-39% for N1-3, 44-58% in N0, 8-22% for unknown N-stage), systemic therapy (38-54%) and radical cystectomy (3-11%). In multivariable analyses adjusting for these patient, tumor, and treatment characteristics, one registry exhibited significantly lower OM (SEER registry 10: hazard ratio [HR] 0.83) and two other registries exhibited significantly higher OM (SEER registries 9: HR 1.13; SEER registry 8: HR 1.24) relative to the largest reference registry (n=1855).CONCLUSIONS: We identified important regional differences that included patient, tumor, and treatment characteristics. Even after adjustment for these characteristics, important OM differences persisted, which may warrant more detailed investigation.

AB - INTRODUCTION: Despite advances in treatment, metastatic urothelial carcinoma of the urinary bladder (mUCUB) is associated with high mortality and treatment risk. We tested for regional differences in mUCUB within a large-scale, population-based database.METHODS: Using the Surveillance, Epidemiology and End Results (SEER) database (2010-2018), patient (age, sex, race/ethnicity), tumor (T-stage, N-stage, number of metastatic sites), and treatment (systemic therapy, radical cystectomy) characteristics were tabulated for mUCUB patients according to 11 SEER registries. Multinomial regression models and multivariable Cox regression models tested overall mortality (OM), adjusting for patient, tumor and treatment characteristics.RESULTS: In 4817 mUCUB patients, registry-specific patient counts ranged from 1855 (38.5%) to 105 (2.2%). Important inter-regional differences existed for race/ethnicity (3-36% for others than non-Hispanic Whites), N-stage (28-39% for N1-3, 44-58% in N0, 8-22% for unknown N-stage), systemic therapy (38-54%) and radical cystectomy (3-11%). In multivariable analyses adjusting for these patient, tumor, and treatment characteristics, one registry exhibited significantly lower OM (SEER registry 10: hazard ratio [HR] 0.83) and two other registries exhibited significantly higher OM (SEER registries 9: HR 1.13; SEER registry 8: HR 1.24) relative to the largest reference registry (n=1855).CONCLUSIONS: We identified important regional differences that included patient, tumor, and treatment characteristics. Even after adjustment for these characteristics, important OM differences persisted, which may warrant more detailed investigation.

U2 - 10.5489/cuaj.8442

DO - 10.5489/cuaj.8442

M3 - SCORING: Journal article

C2 - 37787591

VL - 17

SP - E412-419

JO - CUAJ-CAN UROL ASSOC

JF - CUAJ-CAN UROL ASSOC

SN - 1911-6470

IS - 12

ER -